Assertio (ASRT) Competitors $0.68 -0.01 (-1.84%) As of 11:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ASRT vs. CMPS, SEPN, CADL, DSGN, AVIR, ZYBT, CRVS, MBX, IMMP, and PRMEShould you be buying Assertio stock or one of its competitors? The main competitors of Assertio include COMPASS Pathways (CMPS), Septerna (SEPN), Candel Therapeutics (CADL), Design Therapeutics (DSGN), Atea Pharmaceuticals (AVIR), Zhengye Biotechnology (ZYBT), Corvus Pharmaceuticals (CRVS), MBX Biosciences (MBX), Immutep (IMMP), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry. Assertio vs. COMPASS Pathways Septerna Candel Therapeutics Design Therapeutics Atea Pharmaceuticals Zhengye Biotechnology Corvus Pharmaceuticals MBX Biosciences Immutep Prime Medicine COMPASS Pathways (NASDAQ:CMPS) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, community ranking, dividends and earnings. Does the media prefer CMPS or ASRT? In the previous week, COMPASS Pathways had 6 more articles in the media than Assertio. MarketBeat recorded 7 mentions for COMPASS Pathways and 1 mentions for Assertio. Assertio's average media sentiment score of 1.89 beat COMPASS Pathways' score of 0.68 indicating that Assertio is being referred to more favorably in the news media. Company Overall Sentiment COMPASS Pathways Positive Assertio Very Positive Which has more volatility & risk, CMPS or ASRT? COMPASS Pathways has a beta of 2.29, indicating that its stock price is 129% more volatile than the S&P 500. Comparatively, Assertio has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Do institutionals & insiders hold more shares of CMPS or ASRT? 46.2% of COMPASS Pathways shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 4.3% of COMPASS Pathways shares are held by company insiders. Comparatively, 3.2% of Assertio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor CMPS or ASRT? Assertio received 45 more outperform votes than COMPASS Pathways when rated by MarketBeat users. However, 81.48% of users gave COMPASS Pathways an outperform vote while only 59.68% of users gave Assertio an outperform vote. CompanyUnderperformOutperformCOMPASS PathwaysOutperform Votes6681.48% Underperform Votes1518.52%AssertioOutperform Votes11159.68% Underperform Votes7540.32% Which has stronger valuation & earnings, CMPS or ASRT? COMPASS Pathways has higher earnings, but lower revenue than Assertio. Assertio is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCOMPASS PathwaysN/AN/A-$118.46M-$2.30-1.26Assertio$124.96M0.52-$331.94M-$0.23-2.96 Is CMPS or ASRT more profitable? COMPASS Pathways has a net margin of 0.00% compared to Assertio's net margin of -54.46%. Assertio's return on equity of 3.79% beat COMPASS Pathways' return on equity.Company Net Margins Return on Equity Return on Assets COMPASS PathwaysN/A -63.85% -51.97% Assertio -54.46%3.79%1.81% Do analysts rate CMPS or ASRT? COMPASS Pathways presently has a consensus price target of $21.83, indicating a potential upside of 651.58%. Assertio has a consensus price target of $2.75, indicating a potential upside of 303.82%. Given COMPASS Pathways' higher possible upside, analysts plainly believe COMPASS Pathways is more favorable than Assertio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score COMPASS Pathways 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Assertio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCOMPASS Pathways and Assertio tied by winning 8 of the 16 factors compared between the two stocks. Remove Ads Get Assertio News Delivered to You Automatically Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASRT vs. The Competition Export to ExcelMetricAssertioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.55M$6.87B$5.61B$7.68BDividend YieldN/A2.79%5.33%4.02%P/E Ratio-0.927.3523.5018.55Price / Sales0.52208.36376.0088.66Price / Cash1.1265.6738.1734.64Price / Book0.476.256.814.11Net Income-$331.94M$142.34M$3.20B$247.18M7 Day Performance-10.00%-8.43%-5.42%-4.05%1 Month Performance-12.23%-9.99%-0.12%-6.41%1 Year Performance-29.01%-12.60%7.61%-2.08% Assertio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASRTAssertio2.3386 of 5 stars$0.68-1.5%$2.75+303.8%-27.9%$64.55M$124.96M-0.9220Positive NewsCMPSCOMPASS Pathways3.3404 of 5 stars$3.11+0.3%$21.83+602.0%-64.7%$288.21MN/A-1.41120Analyst ForecastNews CoverageSEPNSepterna2.1084 of 5 stars$6.37+7.6%$34.00+433.8%N/A$282.85M$981,000.000.00N/AEarnings ReportAnalyst ForecastCADLCandel Therapeutics2.6349 of 5 stars$8.66+7.4%$21.00+142.5%+276.6%$281.24M$120,000.00-5.0160DSGNDesign Therapeutics1.961 of 5 stars$4.93+6.0%$8.00+62.3%+4.5%$279.84MN/A-5.8040Gap UpAVIRAtea Pharmaceuticals2.6441 of 5 stars$3.20-0.6%$6.88+115.0%-27.5%$273.68MN/A-1.5570ZYBTZhengye BiotechnologyN/A$5.80+18.9%N/AN/A$273.56M$189.75M0.00278High Trading VolumeCRVSCorvus Pharmaceuticals2.2797 of 5 stars$4.25-1.4%$12.38+191.2%+89.9%$273.09MN/A-4.5730Earnings ReportAnalyst RevisionMBXMBX Biosciences1.9273 of 5 stars$8.13+3.0%$37.25+358.2%N/A$271.74MN/A0.0036Gap DownIMMPImmutep1.6822 of 5 stars$1.84-2.1%$8.50+362.0%-20.2%$267.83M$5.14M0.002,021Gap DownPRMEPrime Medicine2.7546 of 5 stars$2.03+4.1%$13.38+558.9%-71.6%$266.26M$2.98M-0.99234Gap Down Remove Ads Related Companies and Tools Related Companies COMPASS Pathways Competitors Septerna Competitors Candel Therapeutics Competitors Design Therapeutics Competitors Atea Pharmaceuticals Competitors Zhengye Biotechnology Competitors Corvus Pharmaceuticals Competitors MBX Biosciences Competitors Immutep Competitors Prime Medicine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASRT) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ASRT Stock Free ASRT Stock Alerts